Chugai Pharmaceutical Co., the Japanese unit of Roche Holding AG, said first-quarter profit fell 50 percent from a year earlier because of a drop in sales of Tamiflu and Epogin, two of its three best-selling medicines.
Net income fell to ¥6.7 billion in the three months ended March 31, from ¥13.3 billion a year earlier, the Tokyo-based company said. Sales fell 27 percent to ¥66.2 billion, Chugai said.
Unable to view this article?
This could be due to a conflict with your ad-blocking or security software.
Please add japantimes.co.jp and piano.io to your list of allowed sites.
We humbly apologize for the inconvenience.